FIELD: chemistry.
SUBSTANCE: present invention pertains to the cycloalkyl derivative of 3-hydroxy-4-pyridinine with general formula 
, where R1 represents X with the condition that, R2 is Y; or R1 is T with the condition that, R2 is W; or R1 is X with the condition that, R2R5N taken together, form a heterocyclic ring, formed from morpholinyl or piperazinyl, where the morpholinyl or piperazinyl group is either unsubstituted or substituted with between one to three C1-C6 alkyl groups; X is C3-C6 cycloalkyl; Y is chosen from a group consisting of C3-C6 cycloalkyl, C1-C6 alkyl and C1-C6 alkyl, monosubstituted with C3-C6 cycloalkyl; T represents C1-C6 alkyl; W represents C3-C6 cycloalkyl; R3 represents hydrogen; R4 is chosen from a group consisting of hydrogen and C1-C6 alkyl. The invention also relates to the method of obtaining the derivative as well as to pharmaceutical compositions based on these compounds and use of these compounds in making medicinal preparations.
EFFECT: obtaining new compounds, which can be used in removing surplus iron from patients suffering from diseases related to iron oversaturation.
17 cl, 17 ex, 8 tbl, 9 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| TREATMENT METHOD | 2012 |
|
RU2621148C2 |
| ANTAGONISTS OF SOMATOSTATIN RECEPTOR SUBTYPE 5 (SSTR5) | 2014 |
|
RU2671958C2 |
| PYRIDINONE DERIVATIVES AS TISSUE TRANSGLUTAMINASE INHIBITORS | 2013 |
|
RU2652987C2 |
| AMIDES OF CONDENSED PIPERIDINE AS MODULATORS OF ION CHANNELS | 2014 |
|
RU2741810C2 |
| CEPHEM COMPOUND OR ITS PHARMACEUTICALLY ACCEPTABLE SALT | 1992 |
|
RU2024530C1 |
| PROLYL HYDROXYLASE INHIBITORS AND APPLICATION METHODS THEREOF | 2007 |
|
RU2429226C9 |
| PRIMARY CARBOXAMIDES AS BTK INHIBITORS | 2014 |
|
RU2708395C2 |
| 1-(4-ISOXAZOLE-5-YL)-1H-PYRAZOLE-1-YL)-2-METHYLPROPANE-2-OL DERIVATIVES AND RELATED COMPOUNDS AS IL-17 AND IFN-GAMMA INHIBITORS FOR TREATMENT OF AUTOIMMUNE DISEASES AND CHRONIC INFLAMMATION | 2018 |
|
RU2785342C2 |
| TAXOL DERIVATIVES WITH ANTICANCER ACTIVITY | 2007 |
|
RU2419622C2 |
| SUBSTITUTED BENZENE COMPOUNDS | 2013 |
|
RU2658919C2 |
